O	0	11	Requirement	Requirement	NN	B-NP
O	12	14	of	of	IN	B-PP
O	15	23	estrogen	estrogen	NN	B-NP
O	24	32	receptor	receptor	NN	I-NP
O	33	43	expression	expression	NN	I-NP
O	44	47	and	and	CC	O
O	48	56	function	function	NN	B-NP
O	57	60	for	for	IN	B-PP
O	61	62	[	[	(	B-NP
O	62	67	12Val	12Val	NN	I-NP
O	67	68	]	]	)	I-NP
O	69	70	K	K	NN	I-NP
O	70	71	-	-	HYPH	B-NP
O	71	74	Ras	Ras	NN	I-NP
O	74	75	-	-	HYPH	B-NP
O	75	83	mediated	mediate	VBN	I-NP
B-Cell	84	90	NIH3T3	NIH3T3	NN	I-NP
I-Cell	91	95	cell	cell	NN	I-NP
O	96	110	transformation	transformation	NN	I-NP
O	110	111	.	.	.	O

O	113	115	We	We	PRP	B-NP
O	116	128	investigated	investigate	VBD	B-VP
O	129	132	the	the	DT	B-NP
O	133	143	biological	biological	JJ	I-NP
O	144	156	significance	significance	NN	I-NP
O	157	159	of	of	IN	B-PP
O	160	168	estrogen	estrogen	NN	B-NP
O	169	178	receptors	receptor	NNS	I-NP
O	179	180	(	(	(	O
O	180	183	ERs	ER	NNS	B-NP
O	183	184	)	)	)	O
O	185	187	in	in	IN	B-PP
B-Cell	188	194	NIH3T3	NIH3T3	NN	B-NP
I-Cell	195	199	cell	cell	NN	I-NP
O	200	214	transformation	transformation	NN	I-NP
O	215	217	by	by	IN	B-PP
O	218	221	the	the	DT	B-NP
O	222	223	[	[	(	I-NP
O	223	228	12Val	12Val	NN	I-NP
O	228	229	]	]	)	I-NP
O	230	231	K	K	NN	I-NP
O	231	232	-	-	HYPH	B-NP
O	232	235	Ras	Ras	NN	I-NP
O	236	242	mutant	mutant	NN	I-NP
O	242	243	.	.	.	O

O	244	248	This	This	DT	B-NP
O	249	255	mutant	mutant	NN	I-NP
O	256	264	enhanced	enhance	VBD	B-VP
O	265	268	the	the	DT	B-NP
O	269	275	steady	steady	JJ	I-NP
O	275	276	-	-	HYPH	I-NP
O	276	281	level	level	NN	I-NP
O	282	285	and	and	CC	I-NP
O	286	301	transcriptional	transcriptional	JJ	I-NP
O	302	310	activity	activity	NN	I-NP
O	311	313	of	of	IN	B-PP
O	314	316	ER	ER	NN	B-NP
O	316	317	.	.	.	O

O	318	330	Coexpression	Coexpression	NN	B-NP
O	331	333	of	of	IN	B-PP
O	334	337	the	the	DT	B-NP
O	338	350	progesterone	progesterone	NN	I-NP
O	351	359	receptor	receptor	NN	I-NP
O	360	364	with	with	IN	B-PP
O	365	371	mutant	mutant	JJ	B-NP
O	372	373	K	K	NN	I-NP
O	373	374	-	-	HYPH	B-NP
O	374	377	Ras	Ras	NN	I-NP
O	378	381	led	lead	VBD	B-VP
O	382	384	to	to	TO	B-PP
O	385	396	suppression	suppression	NN	B-NP
O	397	399	of	of	IN	B-PP
O	400	414	tumorigenicity	tumorigenicity	NN	B-NP
O	415	418	and	and	CC	I-NP
O	419	429	inhibition	inhibition	NN	I-NP
O	430	432	of	of	IN	B-PP
O	433	436	the	the	DT	B-NP
O	437	447	activation	activation	NN	I-NP
O	448	450	of	of	IN	B-PP
O	451	453	ER	ER	NN	B-NP
O	453	454	.	.	.	O

O	455	458	The	The	DT	B-NP
O	459	468	antisense	antisense	JJ	I-NP
O	469	478	oligomers	oligomer	NNS	I-NP
O	479	492	complementary	complementary	JJ	B-ADJP
O	493	495	to	to	TO	B-PP
O	496	499	the	the	DT	B-NP
O	500	502	ER	ER	NN	I-NP
O	503	513	suppressed	suppress	VBD	B-VP
O	514	527	proliferation	proliferation	NN	B-NP
O	528	531	and	and	CC	O
O	532	543	transformed	transform	VBN	B-NP
O	544	554	phenotypes	phenotype	NNS	I-NP
O	555	557	of	of	IN	B-PP
B-Cell	558	562	K12V	K12V	NN	B-NP
I-Cell	563	568	cells	cell	NNS	I-NP
O	568	569	.	.	.	O

O	570	575	These	These	DT	B-NP
O	576	588	observations	observation	NNS	I-NP
O	589	596	support	support	VBP	B-VP
O	597	600	the	the	DT	B-NP
O	601	611	importance	importance	NN	I-NP
O	612	614	of	of	IN	B-PP
O	615	617	ER	ER	NN	B-NP
O	618	620	in	in	IN	B-PP
O	621	624	Ras	Ras	NN	B-NP
O	624	625	-	-	HYPH	B-NP
O	625	633	mediated	mediate	VBN	I-NP
B-Cell	634	638	cell	cell	NN	I-NP
O	639	653	transformation	transformation	NN	I-NP
O	653	654	.	.	.	O

